As a postdoctoral researcher at Johns Hopkins Medicine, my work focuses on understanding RAS molecular pathway alterations and resistance mechanisms in pancreatic cancer and melanoma. I earned my PhD in Biomedicine Research from the Complutense University of Madrid (2024) and have contributed to impactful studies, including co-authored publications in high-impact journals such as Cell.

Coming from a rural area in Spain, I deeply value the role of scientific collaboration in overcoming research challenges. The HK Laureate Forum presents a unique opportunity to engage with world-class scientists, fostering meaningful discussions on cutting-edge cancer research. My previous experience as a member of the Asociación Española Contra el Cáncer allowed me to build early-stage networks in oncology, and I aim to expand these connections globally.

I am particularly eager to engage with researchers like Eva Nogales, whose insights I previously experienced at CNIO in Madrid. Her ability to translate fundamental discoveries into breakthroughs is inspiring. By participating in this forum, I hope to exchange ideas, establish collaborations, and contribute to the advancement of cancer research, while developing as an interactive scientist within an innovative global network.

My research focuses on understanding resistance mechanisms in pancreatic cancer and melanoma, with a particular emphasis on RAS molecular pathway alterations. As a postdoctoral researcher at Johns Hopkins Medicine, I investigate how mutations in KRAS and associated signaling components drive therapeutic resistance, aiming to identify novel strategies for overcoming these challenges.

One of my key projects involves studying the concurrent inhibition of SOS1 and MEK in NF1-null melanoma, which has shown promising results in suppressing oncogenic signaling (Marasco et al., Cell, 2024). My research seeks to further unravel the molecular basis of RAS-driven tumors, identifying vulnerabilities that can be targeted to improve treatment responses.

Given the aggressive nature of pancreatic cancer and melanoma, understanding adaptive resistance mechanisms is crucial for developing effective therapeutic interventions. Through this work, I aim to contribute to the growing efforts in precision oncology by integrating molecular biology, targeted therapies, and translational research.

My ultimate goal is to bridge the gap between fundamental discoveries and clinical applications, fostering innovative approaches that improve patient outcomes. The HK Laureate Forum provides an exceptional opportunity to discuss these challenges with leading experts, fostering interdisciplinary collaboration in the fight against cancer.